Related Experiment Video
Updated: Jun 4, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Suppressing tumourigenicity of prostate cancer cells by inhibiting osteopontin expression
Yu Zhang1, Shiva S Forootan, Laleh Kamalian
1Molecular Pathology Laboratory, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 6th Floor, Duncan Building, Daulby Street, Liverpool L69 3GA, UK.
Abstract:
Expression of osteopontin (OPN) is increased in prostate cancer cells. The possibility of utilising the increased OPN as a target to suppress the tumourigenicity was investigated in this study. Small interference RNAs against OPN were transfected into highly malignant DU145 prostate cancer cells, which express high level of OPN prior to the transfections, to establish OPN-suppressed clones. Compared with the control transfectants generated by scrambled RNA, suppressed expression of OPN significantly inhibited cell invasiveness and anchorage-independent growth. Similar results were obtained from in vivo experiments. OPN-suppressed transfectants produced significant reductions in average sizes of subcutaneous tumours after inoculation into nude mice. When the levels of OPN measured in transfectants before injection were related to tumour sizes, the reduction in tumour sizes was not propotionally related to the inhibition in OPN-levels. However, when the levels of OPN were analysed in the tumour tissues, it was found that the reduced OPN expression levels were significantly associated with the reducing tumour sizes. These results showed that changes in OPN levels had occurred after the transfectants were inoculated in mice. This study suggested while OPN can be an effective target for therapeutic suppression of prostate cancer, more effective way than RNAi is needed to inhibit OPN expression.
Insights
Osteopontin (OPN) is a potential target for prostate cancer therapy. Suppressing OPN in cancer cells reduced tumor growth and spread, but more effective methods than RNA interference are needed.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Osteopontin (OPN) expression is elevated in prostate cancer cells.
- Increased OPN correlates with enhanced tumor progression and malignancy.
- OPN represents a potential therapeutic target for prostate cancer treatment.
Purpose of the Study:
- To investigate the efficacy of targeting osteopontin (OPN) to suppress prostate cancer tumorogenicity.
- To evaluate the impact of OPN suppression on cancer cell invasiveness and growth in vitro and in vivo.
Main Methods:
- Small interference RNAs (siRNAs) targeting OPN were used to create OPN-suppressed DU145 prostate cancer cell clones.
- In vitro assays assessed cell invasiveness and anchorage-independent growth.
- In vivo studies involved subcutaneous inoculation of OPN-suppressed cells into nude mice to monitor tumor growth.
Main Results:
- OPN suppression significantly inhibited prostate cancer cell invasiveness and anchorage-independent growth in vitro.
- In vivo, OPN-suppressed transfectants showed significantly reduced subcutaneous tumor sizes in nude mice.
- Reduced OPN expression levels in tumor tissues were significantly associated with smaller tumor sizes, indicating OPN's role in tumor progression.
Conclusions:
- Osteopontin (OPN) is a viable therapeutic target for suppressing prostate cancer progression.
- RNA interference (RNAi) shows promise but may require optimization for sustained OPN inhibition.
- Further research is needed to develop more effective strategies for inhibiting OPN expression in prostate cancer therapy.
